exposure estimates for SWCNT on individual gloves(<strong>to</strong>tal h<strong>and</strong> area) ranged from 217 µg <strong>to</strong> 6020 µg,with most of the SWCNT material appearing on theparts of the gloves in direct contact with surfaces. Resultsfrom experimental studies with various typesof nanoparticles found that dermal penetration ofnanoparticles may occur under certain conditions ofexposure (e.g., flexing of skin) [Ryman-Rasmussenet al. 2006; Rouse et al. 2007] <strong>and</strong> that fac<strong>to</strong>rs suchas size, shape, water solubility, <strong>and</strong> surface coatingdirectly affect a nanoparticle’s potential <strong>to</strong> penetratethe skin [Sayes et al. 2004; Ryman-Rasmussen et al.2006]. The results from in vitro studies, using primaryor cultured human skin cells <strong>and</strong> engineered humanskin, show that SWCNT <strong>and</strong> MWCNT are able <strong>to</strong>enter cells <strong>and</strong> cause the release of pro-inflamma<strong>to</strong>rycy<strong>to</strong>kines, induce free radical generation <strong>and</strong> oxidativestress, <strong>and</strong> decrease cell viability [Shvedova etal. 2003; Monteiro-Riviere et al. 2005; Murray et al.2009; Vankoningsloo et al. 2010]. Vankoningslooet al. [2010] also found the surface properties ofMWCNT played a determinant role in their interactionwith cells, <strong>and</strong> when nanotube agglomerationwas decreased, there was an increase in cy<strong>to</strong><strong>to</strong>xicityon keratinocytes. The <strong>to</strong>pical application ofSWCNT (160 µg) <strong>to</strong> SKH-1 mice caused inflammationthat was localized around or within the hair follicles;however, no significant changes were observedat the lowest dose (40 µg) tested [Murray et al. 2009].It was concluded that <strong>to</strong>pical exposure <strong>to</strong> unpurifiedSWCNT at doses > 80 µg/mouse are capable of inducingfree radical generation, oxidative stress, <strong>and</strong>inflammation. However, the results of dermal <strong>to</strong>xicitytesting with one type of MWCNT (Baytubes®) foundno evidence of acute skin irritation or sensitization<strong>and</strong> only mild eye irritation in rabbits when tested according<strong>to</strong> OECD test guidelines [Pauluhn 2010b].Given the limited amount of data on dermal exposure<strong>to</strong> CNT <strong>and</strong> CNF, it would be prudent <strong>to</strong> wearprotective clothing <strong>and</strong> gloves when••all technical measures <strong>to</strong> eliminate or controlthe release of exposure <strong>to</strong> CNT <strong>and</strong> CNFhave not been successful, or••in emergencies.If protective clothing <strong>and</strong>/or gloves are worn,particular attention should be given <strong>to</strong> preventingCNT <strong>and</strong> CNF exposure <strong>to</strong> abraded or laceratedskin. Based on limited experimental evidence,airtight fabrics made of nonwoven textile seem<strong>to</strong> be more efficient in protecting workers againstnanoparticles than fabrics made of woven cot<strong>to</strong>nor polyester [Golanski et al. 2009; Golanski et al.2010]. The results of a study designed <strong>to</strong> evaluatethe penetration of nano- <strong>and</strong> submicron particlepenetration through various nonwoven fabricsfound minimal penetration (< 5%) of iron oxideparticles (< 100 nm) through nonwoven fabricstypically used for hospital frocks, hoodless coveralls,<strong>and</strong> firefighter ensemble insulation [Gao et al.2011]. The challenge when selecting appropriateprotective apparel is <strong>to</strong> strike a balance betweencomfort <strong>and</strong> protection. Garments that provide thehighest level of protection (e.g., an impermeableLevel A suit) are also the least comfortable <strong>to</strong> wearfor long periods of time, while garments that areprobably the least protective (e.g., thin cot<strong>to</strong>n labcoat) are the most breathable <strong>and</strong> comfortable <strong>to</strong>wear. The efficiency of commercial gloves <strong>to</strong> preventdermal exposure <strong>to</strong> nanoparticles varies dependingon the glove material, its thickness, <strong>and</strong>the manner in which it is used (e.g., long exposuretimes, other chemical exposures) [NanoSafe 2008;Golanski et al. 2009, 2010]. The proper selection ofgloves should take in<strong>to</strong> account the resistance ofthe glove <strong>to</strong> the chemical attack by both the nanomaterial<strong>and</strong>, if suspended in liquids, the liquid[USDOE 2007]. If protective gloves (e.g., nitrile,neoprene, latex) are used then “double gloving”may be needed when the worker requires physicalprotection (e.g., working with sharp instruments)in addition <strong>to</strong> chemical protection. Special attentionshould also be given <strong>to</strong> the proper removal <strong>and</strong>disposal of contaminated gloves <strong>to</strong> prevent skincontamination. Gloves should also be visually inspectedfor tears <strong>and</strong> routinely replaced.6.6 Respira<strong>to</strong>rsWhen engineering controls <strong>and</strong> work practicescannot reduce worker CNT <strong>and</strong> CNF exposures64 NIOSH CIB 65 • <strong>Carbon</strong> <strong>Nanotubes</strong> <strong>and</strong> <strong>Nanofibers</strong>
<strong>to</strong> below the REL, then workers should be providedrespira<strong>to</strong>ry protection. The use of respira<strong>to</strong>rsmay also be advisable for certain work tasksthat place workers at risk of potentially highpeak concentrations of CNT <strong>and</strong> CNF (e.g., thecleanup of CNT <strong>and</strong> CNF spills or debris, maintenanceof equipment used <strong>to</strong> process CNT- <strong>and</strong>CNF-materials, the cleaning or disposal of filtrationsystems used <strong>to</strong> capture CNT <strong>and</strong> CNF aerosols).The OSHA respira<strong>to</strong>ry protection st<strong>and</strong>ard (29CFR 1910.134) sets out the elements of a respira<strong>to</strong>rprogram for both voluntary <strong>and</strong> required respira<strong>to</strong>ruse. When respira<strong>to</strong>rs are provided for workerprotection, the OSHA respira<strong>to</strong>ry protection st<strong>and</strong>ardrequires that a respira<strong>to</strong>ry protection programbe established 29 CFR 1910 (c)(1). Elements of theprogram include (1) a medical evaluation of theworker’s ability <strong>to</strong> perform the work while wearinga respira<strong>to</strong>r; (2) regular training of personnel; (3)periodic workplace exposure moni<strong>to</strong>ring; (4) proceduresfor selecting respira<strong>to</strong>rs; (5) respira<strong>to</strong>r fittesting;<strong>and</strong> (6) respira<strong>to</strong>r maintenance, inspection,cleaning, <strong>and</strong> s<strong>to</strong>rage. The effectiveness of the programshould be evaluated regularly <strong>and</strong> respira<strong>to</strong>rsshould be selected by the person who is in chargeof the program <strong>and</strong> knowledgeable about the workplace<strong>and</strong> the limitations associated with each type ofrespira<strong>to</strong>r. The voluntary use of respira<strong>to</strong>rs are permitted,but must comply with the provisions set forthin CFR 1910.134(c)(2)(i) <strong>and</strong> 1910.134(c)(2)(ii).Based on published workplace moni<strong>to</strong>ring datafor CNT [Maynard et al. 2004; Han et al. 2008a;Bello et al. 2008, 2009, 2010; Dahm et al. 2011]<strong>and</strong> CNF [Methner et al. 2007; Evans et al. 2010],a NIOSH-approved filtering facepiece respira<strong>to</strong>r,or elas<strong>to</strong>meric half-facepiece particulate respira<strong>to</strong>requipped with a 95 or 100 series filter, should provideadequate protection when properly fit-testedon the worker [Shaffer <strong>and</strong> Rengasamy 2009], <strong>and</strong>where engineered controls have been installed <strong>to</strong>reduce exposures. A properly fit-tested, half-facepieceparticulate respira<strong>to</strong>r or a filtering facepiece respira<strong>to</strong>rwill provide protection at exposure concentrationsup <strong>to</strong> 10 times the REL. Other classes ofrespira<strong>to</strong>rs are available that provide a higher levelof protection (Table 6–8). The publication NIOSHRespira<strong>to</strong>r Selection Logic 2004 provides guidancefor selecting an appropriate respira<strong>to</strong>r [NIOSH 2005].When selecting the appropriate respira<strong>to</strong>r, therespira<strong>to</strong>r program manager should consider theparticle size in which workers will be potentiallyexposed [Rengasamy <strong>and</strong> Eimer 2011], <strong>and</strong> thepresence of other workplace aerosols. Based on thisinformation, the respira<strong>to</strong>r program manager maydecide <strong>to</strong> choose a respira<strong>to</strong>r with a higher assignedprotection fac<strong>to</strong>r (APF) or choose a respira<strong>to</strong>rwith a higher level of filtration performance (e.g.,changing from an N95 <strong>to</strong> a P100). Studies on thefiltration performance of N-95 filtering facepiecerespira<strong>to</strong>rs have found that the mean penetrationlevels for 40 nm particles range from 1.4% <strong>to</strong> 5.2%,indicating that 95 <strong>and</strong> higher performing respira<strong>to</strong>rfilters would be effective at capturing airborneCNT <strong>and</strong> CNF [Bałazy et al. 2006; Rengasamyet al. 2007, 2008]. Recent studies also show thatnanoparticles
- Page 1 and 2:
CURRENT INTELLIGENCE BULLETIN 65Occ
- Page 3 and 4:
Current Intelligence Bulletin 65Occ
- Page 5 and 6:
ForewordThe Occupational Safety and
- Page 7 and 8:
Executive SummaryOverviewCarbon nan
- Page 9 and 10:
2009; Pauluhn 2010a; Porter et al.
- Page 11 and 12:
neurogenic sig nals from sensory ir
- Page 13 and 14:
possible. Until the results from an
- Page 15 and 16:
••Follow exposure and hazard as
- Page 17 and 18:
Periodic Evaluations••Evaluatio
- Page 19 and 20:
ContentsForeword ..................
- Page 21 and 22:
A.3.2 Comparison of Short-term and
- Page 23 and 24:
ESPFeFMPSFPSSgGMGSDHCLHECHEPAhrISOI
- Page 25 and 26:
AcknowledgementsThis Current Intell
- Page 27 and 28:
1 IntroductionMany nanomaterial-bas
- Page 29:
2 Potential for ExposureThe novel a
- Page 32 and 33:
CNMs, with MWCNT agglomerates obser
- Page 34 and 35:
composite materials with local exha
- Page 36 and 37:
information on air contaminants. Sa
- Page 39 and 40: 3 Evidence for Potential Adverse He
- Page 41 and 42: decreasing agglomerate size increas
- Page 43 and 44: examined up to 60 days post-exposur
- Page 45 and 46: 3.3 SWCNT and MWCNTIntraperitoneal
- Page 47 and 48: The same potency sequence was obser
- Page 49 and 50: Table 3-3. Findings from published
- Page 51 and 52: Table 3-5. Findings from published
- Page 53 and 54: Table 3-6. Findings from published
- Page 55 and 56: Table 3-7 (Continued). Findings fro
- Page 57: Table 3-8. Findings from published
- Page 60 and 61: length, respectively) [Muller et al
- Page 63 and 64: 5 CNT Risk Assessment and Recommend
- Page 65 and 66: A-6). Risk estimates derived from o
- Page 67 and 68: Table 5-4. Factors, assumptions, an
- Page 69 and 70: and analytical methods. NIOSH is re
- Page 71 and 72: Table 5-5. Recommended occupational
- Page 73 and 74: deficits in animals or clinically s
- Page 75: (3) Rat lung dose estimationIn the
- Page 78 and 79: tasks where worker exposures exceed
- Page 80 and 81: As part of the evaluation of worker
- Page 82 and 83: Table 6-1. EC LODs and LOQs for 25-
- Page 84 and 85: 6.2 Engineering ControlsOne of the
- Page 86 and 87: Table 6-6 (Continued). Examples of
- Page 88 and 89: Table 6-7 (Continued). Engineering
- Page 92 and 93: Table 6-8. Respiratory protection f
- Page 94 and 95: ••Workers in areas or in jobs w
- Page 97 and 98: 7 Research NeedsAdditional data and
- Page 99 and 100: ReferencesACGIH [1984]. Particle si
- Page 101 and 102: Bolton RE, Vincent HJ, Jones AD, Ad
- Page 103 and 104: eport issued on July 22, 2011. NEDO
- Page 105 and 106: Kobayashi N, Naya M, Mizuno K, Yama
- Page 107 and 108: Methner M, Hodson L, Geraci C [2010
- Page 109 and 110: Human Services, Centers for Disease
- Page 111 and 112: Piegorsch WW, Bailer AF [2005]. Qua
- Page 113 and 114: AD, Baron PA [2003]. Exposure to ca
- Page 115: Varga C, Szendi K [2010]. Carbon na
- Page 119 and 120: ContentsA.1 Introduction ..........
- Page 121 and 122: A.1 IntroductionThe increasing prod
- Page 123 and 124: provide an informal check on the es
- Page 125 and 126: these same dose groups; this effect
- Page 127 and 128: Table A-1. Rodent study information
- Page 129 and 130: the deposited (no clearance) and th
- Page 131 and 132: The other BMDS models failed to con
- Page 133 and 134: Figure A-2. Benchmark dose model (m
- Page 135 and 136: Figure A-3 (continued). Benchmark d
- Page 137 and 138: Table A-3. Benchmark dose estimates
- Page 139 and 140: Table A-5. Benchmark dose estimates
- Page 141 and 142:
histopathology grade 2 or higher lu
- Page 143 and 144:
Table A-8. Working lifetime percent
- Page 145 and 146:
developing early-stage adverse lung
- Page 147 and 148:
Figure A-4. Dose-response relations
- Page 149 and 150:
cell surface area). However, the wo
- Page 151 and 152:
purified or unpurified (with differ
- Page 153 and 154:
Table A-9. Comparison of rat or hum
- Page 155 and 156:
A.6.1.3 Pulmonary Ventilation RateT
- Page 157 and 158:
used as the effect levels in evalua
- Page 159 and 160:
the DF estimate, although a larger
- Page 161 and 162:
or overloading, of particle clearan
- Page 163 and 164:
Table A-13. Human-equivalent retain
- Page 165 and 166:
A.7.1 Particle CharacteristicsBoth
- Page 167 and 168:
and density. The following MMAD and
- Page 169:
Table A-15. CNT lung dose normalize
- Page 172 and 173:
B.1 Key Terms Related toMedical Sur
- Page 175 and 176:
APPENDIX CNIOSH Method 5040
- Page 177 and 178:
filter. In the method evaluation, d
- Page 179 and 180:
Most of the studies on sampling art
- Page 181 and 182:
e analyzed to determine the onset o
- Page 184:
Delivering on the Nation’s promis